Search results
Sio Gene Therapies - Breaking the Boundaries of Gene Therapy. On April 5, 2023, the stockholders of Sio Gene Therapies, Inc. voted to liquidate and dissolve the company.
Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland.
Sio Gene Therapies is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease.
Dec 15, 2022 · Following a monthslong business review, Sio Gene Therapies revealed Thursday plans to shut down the company and liquidate its assets. The plan, put forward by the company’s board of directors, will need to win shareholder approval at a meeting slated to take place in the first quarter.
Nov 1, 2021 · Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients.
Oct 21, 2021 · NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the...
Feb 2, 2024 · Sio was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. Sio ceased its development programs in mid-2022. Its stockholders voted to dissolve Sio and its remaining 3 foreign subsidiaries in April 2023.
